Vaxart, Inc.
NASDAQ:VXRT · NASDAQ Capital Market
-$0.01 today
Vol 0.35M · Avg 0.44M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:VXRT · Revenue to Net Income
Key Ratios
Analysis
$255.6M of revenue converted into $37.1M of net income for the selected period. Gross margin is 100.0% and net margin is 4.3%, showing how much revenue survives after costs and taxes. EPS is $0.14, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $237.3M +726.7% | $28.7M +288.9% | $7.4M +6796.3% | $107.0K -88.0% | $892.0K | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 | $0 -100.0% | $4.5M | $0 -100.0% | $48.7M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $237.3M +726.7% | $28.7M +896.9% | $2.9M +2590.7% | $107.0K +100.2% | -$47.9M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 100.0% +0.0pp | 100.0% +61.0pp | 39.0% -61.0pp | 100.0% +5465.1pp | -5365.1% | 9.8% | 28.9% | 38.3% |
| Research & Development | $201.6M +171.6% | $74.2M +8.9% | $68.1M -15.9% | $81.1M +66.3% | $48.7M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $17.6M -15.3% | $20.8M -8.0% | $22.6M -23.1% | $29.4M +34.2% | $21.9M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $219.2M +130.7% | $95.0M +10.2% | $86.2M -24.8% | $114.7M +360.7% | $24.9M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $8.6M -3.1% | $8.8M +2.6% | $8.6M +48.6% | $5.8M +138.7% | $2.4M | $374.2M | $1.2B | $631.8M |
| EBITDA | $28.2M +151.4% | -$54.9M +23.9% | -$72.1M +28.3% | -$100.6M -51.4% | -$66.5M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 11.9% +203.1pp | -191.2% +786.4pp | -977.5% +93023.4pp | -94000.9% -86551.3pp | -7449.7% | 5.6% | 46.3% | 42.0% |
| Operating Income | $18.1M +127.3% | -$66.3M +20.5% | -$83.3M +27.3% | -$114.6M -57.5% | -$72.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 7.6% +238.6pp | -231.0% +898.5pp | -1129.5% +105961.1pp | -107090.7% -98934.6pp | -8156.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.6M -37.2% | $2.5M -4.1% | $2.7M +112.7% | $1.2M +1439.5% | $81.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $2.8M -4.9% | $3.0M +105.2% | $1.4M +10.9% | $1.3M -11.8% | $1.5M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$1.3M -221.8% | -$395.0K -134.6% | $1.1M -83.4% | $6.9M +188.7% | $2.4M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $16.8M +125.2% | -$66.7M +18.9% | -$82.2M +23.7% | -$107.7M -53.1% | -$70.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 7.1% +239.4pp | -232.4% +881.7pp | -1114.0% +99531.8pp | -100645.8% -92757.6pp | -7888.2% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $476.0K +83.1% | $260.0K -0.4% | $261.0K +289.6% | $67.0K -37.4% | $107.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | $16.3M +124.4% | -$66.9M +18.8% | -$82.5M +23.5% | -$107.8M -52.9% | -$70.5M | $4.9B | $4.8B | $4.7B |
| Net Margin | 6.9% +240.1pp | -233.3% +884.3pp | -1117.6% +99590.8pp | -100708.4% -92808.2pp | -7900.2% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $0 +150.0% | -$0 +17.6% | -$0 +22.7% | -$0 -57.1% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $0 +150.0% | -$0 +17.6% | -$0 +22.7% | -$0 -57.1% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $230.3M -52.7% | $487.3M +0.0% | $487.3M +0.0% | $487.3M +0.0% | $487.3M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $230.3M -52.7% | $487.3M +0.0% | $487.3M +0.0% | $487.3M +0.0% | $487.3M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Relmada Therapeutics, Inc.
NASDAQ:RLMD
$487.67M
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
$155.81M
Immunic, Inc.
NASDAQ:IMUX
$136.78M
Repare Therapeutics Inc.
RPTX
$114.24M
Fortress Biotech, Inc.
NASDAQ:FBIO
$92.02M
CAMP4 Therapeutics Corporation
NASDAQ:CAMP
$89.00M
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
$59.20M
Cibus, Inc.
NASDAQ:CBUS
$55.95M
TScan Therapeutics, Inc.
NASDAQ:TCRX
$55.71M
Acrivon Therapeutics, Inc. Common Stock
ACRV
$46.70M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does VXRT generate?
Vaxart, Inc. (VXRT) reported $237.26M of revenue in fiscal 2025.
Is VXRT profitable?
Vaxart, Inc. (VXRT) reported $16.33M of net income, with a net margin of 6.9%.
Explore More
Continue the stock analysis
Jump to another research area for this company.